DNQX

• UNSPSC Description:

  DNQX (FG 9041), a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively)[1].

• Target Antigen:

  iGluR

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel;Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/DNQX.html

• Solubility:

  DMSO : ≥ 35 mg/mL|H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C1C(NC2=CC([N+]([O-])=O)=C([N+]([O-])=O)C=C2N1)=O

• Molecular Weight:

  252.14

• References & Citations:

  [1]Honoré T, et al. Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science. 1988;241(4866):701-703.|[2]Lee SH, et al. Selective excitatory actions of DNQX and CNQX in rat thalamic neurons. J Neurophysiol. 2010;103(4):1728-1734.|[3]Sharp JW, et al. DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex. Brain Res. 1995;687(1-2):114-124.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2379-57-9